Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > load up load up
View:
Post by Quentin30 on May 26, 2023 4:09pm

load up load up

Back up the truck everybody... ONCY is going to the moon... LOL...

So the company release 'great' data, and the price tanks almost 20%... Jeez good job it wasn't bad data.

So according to Matt Coffey, in 2019, Aware-1 data was all that was needed to get Roche to pull the trigger (presumably on a deal and not just blowing their own brains out).

Then we get Matt telling us that Aware-1 will be done in a few months...Then we get Bracelet-1, and setting up competition between would be partners/buyers...

So Pfizer has pulled out... and ONCY has already signalled that they may not have a CPI - language for, didn't work like we'd hoped... so if there is no value to the Check Point inhibitor company... who, just who is going to pay for the Phase III... and they need to hurry because that patent clock is ticking down...

For a product with such potential, these clowns have done their very best to keep it from succeeding... Even their sole partner Adlai Norttye no longer mentions Pela in the product pipeline...

Noteable may well now be espousing that Pela will be trialled with Car-T, crushed cookies and cream, and any other combo, but if they do not get approval BEFORE the patents run out... it is GAME over.

 and I very much doubt big pharma is in a rush and giddy to do a deal... listen to Canadafan and Noteable, and you'll lose time and again... .only way to make money here, is to trade this tired old dog.
Comment by westcoast1000 on May 26, 2023 4:19pm
Formerly, I thought Quentin was a fretful and worried but sincere poster. Now I think he is a very slick soft basher that is now going harder at it. He is being quoted on ST or Yahoo (I cannot remember which) as an oracle about the failure of the company. That is a tell from my viewpoint. If he held lots of shares long term, bashing your own investment, or telling others to trade it, does not ...more  
Comment by Quentin30 on May 26, 2023 4:34pm
NO evidence... LOL... Pfizer has walked away...  Matt has signalled that we may not have a CPI - he's been priming us for this... so it's not a shock... and sure I repeat myself, are you beginning to see the pattern with ONCY yet..?  How well have the pumpers been doing.. A couple of weeks ago, I stated that the price goes up towards news and reaches a high two days prior ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities